Advanced searches left 3/3

Neurotrophic Keratitis - DOAJ

Summarized by Plex Scholar
Last Updated: 16 September 2022

* If you want to update the article please login/register

Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment

To investigate the management and success of treating patients with stage I Neurotrophic Keratitis patients with an 8-week course of topical recombinant human growth factor. One patient had no change in their pre-treatment physical acuity, while three others had significant decreases in BCVA, and improvements in their quality of life were present in the four patients' study. For all four patients, this case series provides real-world evidence of the safety and effectiveness of cen. . . . min therapy of stage I NK.

Source link: https://doi.org/10.1016/j.ajoc.2022.101649


Neurotrophic keratitis: current challenges and future prospects

Neurotrophic keratitis is a degenerative corneal disease that causes spontaneous epithelial injury and corneal ulceration, according to Professor Piera Versura, Giuseppe Giannaccare, Marco Pellegrini, Marco Pellegrini, Marco Pellegrini, Stefano Sebastiani, Emilio C Campos Ophthalmology Unit, University of Bologna, Italy Abstract: Cert. Bonophoretic keratitis is a degenerative corneal kera kera, kera kera, Graftio, Andrea Puglio kera kera, Stefano Sebastiani, Marco Pellegrini, Emili, Santa, Santa e, Pia a Santa, Santy, Bod's e, Marco Pellegna, Vito Verta, Santa, Giannaccare, Santich Both protective reflexes and trophic neuromodulators, which are essential for vitality, metabolism, and wound healing of ocular surface tissue tissues, are reduced by the impairment of corneal sensory innervation. Any ocular and systemic disease associated with the disease requires careful investigation, complete ocular surface examination, and quantitative measurement of corneal sensitivity. NK alterations range from corneal epithelial destruction to chronic epithelial dysfunction and ulcer, which may progress to corneal perforation.

Source link: https://doaj.org/article/67e2508fa0a140399fc800c6bc20931a


Neurotrophic Keratitis Due to Congenital Corneal Anesthesia with Deafness, Hypotonia, Intellectual Disability, Face Abnormality and Metabolic Disorder: A New Syndrome?

Congenital corneal anesthesia is a very rare disease that necessitates prompt ophthalmologists'u2019 attention in making diagnosis and treatment decisions. Bigeminal hypoplasia and the diagnosis of neurotrophic keratopathy due to bilateral congenital corneal anesthesia was established by brain magnetic resonance imaging. The discrepancy between clinical signs and symptoms or treatment non-response in cases of corneal erosions should warn physicians of trigeminal dysfunction. MRI is the gold standard used to establish congenital corneal anesthesia and to distinguish from other potential neurotrophic keratitis causes.

Source link: https://doi.org/10.3390/medicina58050657


Neuronal Intranuclear Inclusion Disease-Related Neurotrophic Keratitis: A Case Report

Neuronal intranuclear inclusion disease is a rare and slowly progressing neurodegenerative disorder characterized by the presence of eosinophilic neuronal intranuclear inclusions. The clinical manifestations of NIID are diverse, with dementia being the most common first appearance in cases of sporadic NIID. We review an adult female with keratitis as the first presentation of bilateral limb tremor, gait disturbances, overemotional conduct, sweating, and constipation. In the corticomedullary junction obtained with DWI, the patient's diagnosis of NIID was based on the presence of intranuclear inclusions in biopsied skin and the characteristic high-intensity signal.

Source link: https://doi.org/10.3390/brainsci12060782


Synergistic effect of regenerating agent plus cord blood serum eye drops for the treatment of resistant neurotrophic keratitis: a case report and a hypothesis for pathophysiologic mechanism

According to Mackie classification, Corneal disease was resistant to standard treatment and rated as stage 2 on Mackie's list. As the first eye drop, every 5 days in combination with daily cord blood serum drop drops 6 times/day, patient was told to instill regenerating agent eye drops in the morning. This case report, to the best of our knowledge, describes for the first time the unique use of RGTA and CBS eye drops in conjunction with RGTA and CBS eye drops for the treatment of neurotrophic keratitis resistant to conservative therapy. We hypothesize that RGTA eye drops, along with CBS eye drops' growth factors, could increase cell growth over the matrix. Combining RGTA and CBS eye drop therapy may be a new potential treatment for resistant neurotrophic keratitis (recurrent neurotrophic keratitis), especially when each drug alone is not effective.

Source link: https://doaj.org/article/69a49e6af02f41649cd8d5c26b4801d8


Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis

Neurotrophic keratitis, a degenerative disease attributed to damage to the trigeminal nerve, blocks both tearing and blinking reflexes, causing the most common forms of dry eye disease. Both diseases have the same spectrum of corneal pathologies, including inflammation and corneal epithelial keratitis, which can progress to vision-threatening epithelial defect and stromal ulceration. These studies support the safety and effectiveness of cryopreserved AM in restoring corneal epithelial function, improving visual acuity in eyes with NK and DED, and treating symptomatic DED.

Source link: https://doi.org/10.4103/tjo.tjo_5_20


Neurotrophic keratitis after micropulse transscleral diode laser cyclophotocoagulation

To describe two cases of neurotrophic keratitis following micropulse transscleral cyclophotocoagulation, please refer to this article. Observations: Two patients with predisposing causes for reduced corneal sensation developed NK 1 month after MP-TCP was announced. One patient required the use of a bandage contact lens, while the other patient required tarsorrhaphy. Result and importance: NK can be triggered after MP-TCP in patients with underlying causes for decreased corneal sensation, despite previous predisposing factors.

Source link: https://doi.org/10.1016/j.ajoc.2019.100469


Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: A Case Report

A recurrence of severe neurotrophic keratitis on a corneal graft was identified by a 24-year-old woman with a severe neurotrophic keratitis and a lagophthalmos after surgery. CICA's Presentation: The aim of the study was to demonstrate the sensitivity of a novel human recombinant nerve growth factor based ophthalmic keratitis on a corneal graft. CONCLUSION: The case presented here is the first report of a cen. . . . min-based treatment for a NK recurrence after PK, and we note a healthy outcome at one year of follow-up, to our knowledge.

Source link: https://doaj.org/article/38dae677be43464f9206f2fa1288bd9e


Bilateral herpetic keratitis presenting with unilateral neurotrophic keratitis in pemphigus foliaceus: a case report

Abstract Introduction We present an example of bilateral herpetic keratitis in a patient with pemphias foliaceus and unilateral neurotrophic keratitis treated with amniotic membrane transplantation. Case description A 71-year-old Korean man developed bilateral herpetic keratitis just one week after a rapid tapering of systemic corticosteroid. Our patient's right eye had healed, but his left eye revealed more stromal edema with enlarged epithelial defects. Patients with autoimmune disease or immunosuppressive therapy have a higher risk of suffering bilateral herpetic keratitis.

Source link: https://doi.org/10.1186/1752-1947-5-328


Neurotrophic keratitis after penetrating keratoplasty for lattice dystrophy

To report the clinical results of a patient with unilateral neurotrophic keratitis treated with topical recombinant human growth factor. As shown in this case of recurrent neurotrophic keratitis, topical recombinant human nerve growth factor is a novel and cost-effective therapy option that may help with optical quality and patient satisfaction.

Source link: https://doi.org/10.1016/j.ajoc.2021.101058

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions